18F-FDGPET／CT显像评价肝泡型包虫病阿苯达唑脂质体治疗的疗效

18F-FDG PET/CT to evaluate the therapeutic effect of liposomal albendazole on hepatic alveolar echinococcosis

目的分析肝泡型包虫病（HAE）阿苯达唑脂质体治疗前后病灶边缘带放射性分布的变化，探讨18F-脱氧葡萄糖（FDG）PET／CT显像对疗效的评价价值。方法收集2011年7月至2015年7月问明确诊断为HAE患者37例[男21例，女16例；平均年龄（53＋12）岁]，患者均于服药前行18F-FDGPET／CT检查，测量病灶边缘带最大标准摄取值（SUVmax）；按体质量服用阿苯达唑脂质剂10mg·d^-1·kg。6个月后再行全身18F-FDGPET／CT检查，测量SUVmax。采用两样本t检验分析数据。结果37例HAE患者中，阿苯达唑脂质体治疗前SUVmax为4．88±1．86，治疗后病灶边缘增殖浸润带放射性分布有不同程度减低；24例病灶体积缩小者SUVmax为3．63±1．38，较前差异有统计学意义（t=5．24，P〈0．001）。结论18F-FDGPET／CT显像对HAE阿苯达唑脂质体治疗前后肝内病灶活性的判断具有重要意义：HAE病灶边缘带放射性摄取程度可作为疗效评价的重要指标。

Objective To analyze the changes of radioactivity of the marginal zone of hepatic alveolar echinococeosis （HAE） before and after the treatment with albendazole liposomes, and to explore the value of 18F- fluorodeoxyglucose （FDG） PET/CT imaging in therapeutic response. Methods From July 2011 to July 2015, 37 patients （21 males, 16 females; average age （53±12） years） with HAE were selected and underwent 18F-FDG PET/CT imaging before routine medication with albendazole liposomes （ 10 mg · d^-1 · kg^-1 ）, and the maximum standardized uptake value （ SUVmax ） of the margin of lesions was calculated. PET/CT imaging was per- formed again 6 months later to measure the SUVmax of the marginal lesions. Two-sample t test was used to an- alyze the data. Results In 37 patients with HAE, SUVmax before treatment was 4.88± 1.86, which was higher than that of 24 patients with reduced lesion size after treatment （ 3.63± 1.38 ; t = 5.24, P〈 0.001 ）. Conclusion 18F-FDG PET/CT is useful for evaluating the radioactivity of marginal zone of HAE before and after the treatment with albendazole liposomes, and SUVmax of the marginal zone could be valuable for thera- oeutic resoonse evaluation.